{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:03:35Z","timestamp":1781953415476,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.ygyno.2013.04.055","type":"journal-article","created":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T03:23:15Z","timestamp":1367119395000},"page":"295-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers"],"prefix":"10.1016","volume":"130","author":[{"given":"Minh D.","family":"Dao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham K.","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.04.055_bb0005","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0015","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2008.12.008","article-title":"Surveillance of patients after initial treatment of ovarian cancer","volume":"71","author":"Gadducci","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0093-7754(03)00100-3","article-title":"The follow-up of ovarian cancer","volume":"30","author":"Vaidya","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0035","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0b013e31823532ce","article-title":"Extraperitoneal metastases from recurrent ovarian cancer","volume":"22","author":"Robinson","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0050","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/cncr.25967","article-title":"Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study","volume":"117","author":"McGonigle","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0055","author":"Morgan"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0060","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0065","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1200\/JCO.2005.02.2582","article-title":"Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range","volume":"23","author":"Santillan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0075","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","article-title":"Frequency of symptoms of ovarian cancer in women presenting to primary care clinics","volume":"291","author":"Goff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0090-8258(91)90099-Q","article-title":"Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer","volume":"40","author":"Burghardt","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0090","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1097-0142(19871001)60:7<1561::AID-CNCR2820600725>3.0.CO;2-V","article-title":"Distant metastases in epithelial ovarian carcinoma","volume":"60","author":"Dauplat","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ygyno.2005.06.051","article-title":"Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors","volume":"99","author":"Takeshima","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0100","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/annonc\/mdq229","article-title":"Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study","volume":"21","author":"Sehouli","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0105","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1525-1438.2005.00143.x","article-title":"Brain metastases from epithelial ovarian cancer","volume":"15","author":"Tay","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0110","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0115","first-page":"310","article-title":"The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary","volume":"176","author":"van der Burg","year":"1993","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","article-title":"Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients","volume":"12","author":"Coleman","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.bjc.6601501","article-title":"Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?","volume":"90","author":"Gronlund","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0140","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/cncr.23374","article-title":"Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy","volume":"112","author":"Azad","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0145","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2011.11.035","article-title":"Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial","volume":"124","author":"Randall","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.055_bb0150","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813003119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813003119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T13:25:30Z","timestamp":1539696330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813003119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0090825813003119"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.055","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}